Seminars in Radiation Oncology, Год журнала: 2025, Номер 35(2), С. 285 - 300
Опубликована: Март 14, 2025
Язык: Английский
Insights into Imaging, Год журнала: 2024, Номер 15(1)
Опубликована: Фев. 5, 2024
Abstract Background In patients treated for head and neck cancer, imaging studies are usually obtained within 3–6 months after treatment assessment of response. After 6 months, most guidelines advocate clinical follow-up, with reserved clinically suspect or equivocal findings. However, some do recommend systematic surveillance, many clinicians tend to include type in their follow-up schemes. Objectives This review focuses on the usefulness routine (systematic) post-treatment surveillance cancer beyond first 3–6-month baseline study. Methods A literature search was conducted using PubMed Google Scholar. Additional were identified by reviewing reference lists. Only original papers considered. Results compared symptom-directed and/or finding-directed imaging. Five hundred twenty-one records through database search, 44 additional other sources. Forty-eight articles selected final review. Analysis these showed that almost half cases locoregional recurrences metastases only detected (40.9%), mean time detection recurrent metastatic disease (11.5 months) well period scan. Most authors reported superior results PET-CT when techniques. Conclusion Strong arguments found favor advanced during at least one preferably 2 years treatment. Critical relevance statement suggests may currently be underused cancer. Key points • long-term 521 revealed allowed initial more than 40% patients. Imaging Graphical
Язык: Английский
Процитировано
6
Cancers, Год журнала: 2022, Номер 14(12), С. 2968 - 2968
Опубликована: Июнь 16, 2022
As the seventh most common cancer globally, head and neck cancers (HNC) exert considerable disease burden, with an estimated 277,597 deaths worldwide in 2020 alone. Traditional risk factors for HNC include tobacco, alcohol, betel nut; more recently, human papillomavirus has emerged as a distinct driver of disease. Currently, limitations screening surveillance methods often lead to identifying advanced stages, associated poor outcomes. Liquid biopsies, particular circulating tumor DNA (ctDNA), offer potential enhancing screening, early diagnosis, patients, improvements patient In this review, we examine current methodologies detecting ctDNA highlight research illustrating viral non-viral biomarker utilities treatment response, prognosis. We also summarize challenges future directions testing patients.
Язык: Английский
Процитировано
23
Cell Death and Differentiation, Год журнала: 2024, Номер 31(4), С. 460 - 468
Опубликована: Фев. 26, 2024
Abstract Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. Molecular residual disease (MRD) detection using multiple assays after definitive therapy has not been reported. In this study, we included LA-HNSCC (stage III Human Papilloma virus (HPV)-positive, III-IVB HPV-negative) treated curative intent. Plasma was collected pre-treatment, at 4–6 weeks (FU1) 8-12 (FU2) post-treatment. Circulating tumor DNA (ctDNA) analyzed a tumor-informed (RaDaR®) tumor-naïve (CAPP-seq) assay. HPV measured HPV-sequencing (HPV-seq) digital PCR (dPCR). A total 86 plasma samples from 32 were analyzed; all least 1 follow-up sample. Most stage HPV-positive (50%) received chemoradiation (78%). No had radiological FU2. With median 25 months, there 7 clinical relapses. ctDNA baseline detected in 15/17 (88%) by RaDaR associated recurrence free survival (RFS). Two relapsed within year showed MRD FU2 RaDaR; during shorter RFS ( p < 0.001). CAPP-seq pre-treatment = 0.09). HPV-seq or dPCR Sensitivity specificity for 40% 100% versus 20 90.5% CAPP-seq. 91.7% 50% dPCR. conclusion, can be before therapy. The assay but may detect who relapse year. more sensitive than detection.
Язык: Английский
Процитировано
5
JAMA Otolaryngology–Head & Neck Surgery, Год журнала: 2024, Номер 150(5), С. 444 - 444
Опубликована: Апрель 4, 2024
Importance The utility of preoperative circulating tumor tissue-modified viral human papillomavirus DNA (TTMV-HPV DNA) levels in predicting (HPV)–associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) disease burden is unknown. Objective To determine if HPV (ctHPVDNA) associated with patients HPV+ OPSCC who have undergone transoral robotic surgery (TORS). Design, Setting, and Participants This cross-sectional study comprised underwent primary TORS between September 2021 April 2023 at one tertiary academic institution. Patients treatment-naive (p16-positive) ctHPVDNA were included, those neck mass excision before collection excluded. Main Outcomes Measures main outcome was the association increasing size lymph node involvement surgical pathology. secondary adverse pathology, which included lymphovascular invasion, perineural or extranodal extension. Results A total 70 (65 men [93%]; mean [SD] age, 61 [8] years). Baseline ranged from 0 fragments/milliliter plasma (frag/mL) to 49 452 frag/mL (median [IQR], 272 [30-811] frag/mL). Overall, 58 (83%) had positive results for ctHPVDNA, 1 (1.4%) indeterminate results, 11 (15.6%) negative results. sensitivity detectable identifying pathology-confirmed 84%. Twenty-seven (39%) pathologic (pT) staging pT0 pT1, 34 (49%) pT2 staging, 9 (13%) pT3 pT4 staging. No clinically meaningful difference undetectable cohorts found Although median appeared be higher through stages pN1 pN2 stages, effect sizes small (pT stage: η2, 0.002 [95% CI, −1.188 0.827]; pN 0.043 −0.188 2.600]). Median log(TTMV-HPV active smokers (8.79 3.55-5.76]), compared never (5.92 −0.97 1.81]) former (4.99 0.92-6.23]). Regression analysis did not show an dimension metastatic deposit DNA). After univariate analysis, no Conclusions Relevance In this study, TORS.
Язык: Английский
Процитировано
5
Cancers, Год журнала: 2022, Номер 14(16), С. 3894 - 3894
Опубликована: Авг. 11, 2022
A minority of patients with metastatic head and neck squamous cell carcinoma (HNSCC) present oligometastatic disease. Oligometastasis not only reflects a disease state, but might also an opportunity for cure in the setting. Radical ablation all sites may confer prolonged survival possibly achieve some patients. However, substantial debate remains about whether could benefit from curative intent therapy or aggressive treatments expose to futile toxicity. Optimal selection patients, carefully balancing currently known prognostic factors against risks toxicity is critical. Emerging evidence suggests that limited burden disease, viral-related pharyngeal cancer, metachronous metastasis lung-only most this approach. Efforts are underway identify biomarkers can detect oligometastasis better select who would derive maximum radical The combination radiotherapy immunotherapy promises enhance anti-tumoral immune response help overcome resistance. optimization management algorithms, including patient selection, radiation dose sequencing, will be critical upcoming clinical trials. This review summarizes recent knowledge characteristics investigational efforts regarding HNSCC.
Язык: Английский
Процитировано
21
Clinica Chimica Acta, Год журнала: 2023, Номер 542, С. 117269 - 117269
Опубликована: Фев. 24, 2023
Язык: Английский
Процитировано
11
Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(1), С. e008436 - e008436
Опубликована: Янв. 1, 2024
Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous carcinoma and biomarkers predictive of response are greatly needed. This multicenter phase II clinical trial (NCT02919969) enrolled metastatic or locally advanced incurable (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint the was objective rate (ORR). Exploratory objectives included analysis potential including assessment tumor-associated immune populations multichannel immunofluorescence circulating tumor tissue modified viral-human papillomavirus DNA (TTMV-HPV DNA) using serially collected blood samples. To characterize features long-term responders, we combined data from our prospective a retrospective cohort cancer treated anti-PD-1 (n=18). In study, ORR to monotherapy 9.4% median progression-free survival 2.2 months. Despite high level HPV positivity observed TTMV-HPV testing, majority had low levels CD8+PD-1+ T cells on pretreatment biopsy. who benefited decreasing scores complete responder's became undetectable. Long-term responses were in one patient (5.3 years) three (2.5, 6, 8 cohort. responders HPV-positive tumors, lacked liver metastases, achieved radiological response. Pembrolizumab has durable efficacy rare subset cancers. However, despite persistence infection, indicated by DNA, most cancers have numbers resistant pembrolizumab.
Язык: Английский
Процитировано
4
American Journal of Otolaryngology, Год журнала: 2024, Номер 45(3), С. 104243 - 104243
Опубликована: Фев. 28, 2024
Язык: Английский
Процитировано
4
Oral Oncology, Год журнала: 2024, Номер 155, С. 106874 - 106874
Опубликована: Июнь 14, 2024
Язык: Английский
Процитировано
4
Cancers, Год журнала: 2025, Номер 17(2), С. 174 - 174
Опубликована: Янв. 8, 2025
The incidence and mortality of anal squamous cell carcinoma (ASCC) are rising, with greater than 80% cases linked to human papillomavirus (HPV), primarily HPV16. Post-treatment surveillance can be challenging due the limitations anoscopy, digital rectal exam (DARE), imaging. Plasma tumor tissue modified viral (TTMV)-HPV DNA has shown strong sensitivity, specificity, predictive value in detecting recurrence HPV-driven oropharyngeal cancer. Here, we investigate ability TTMV-HPV for early detection ASCC. This retrospective clinical case series included 117 patients ASCC across 7 U.S. centers, monitored during routine care between March 2020 June 2024. Physician-reported data biomarker testing were combined create a comprehensive, longitudinal dataset evaluating test performance metrics. Patients had median age 63 years post-diagnosis follow-up 19 months. HPV status was confirmed by (52%) or p16 immunohistochemistry (39%). Of those tested pretreatment, 85% positive result. clearance within three months post-treatment associated significantly better recurrence-free survival. per-patient (PPV), negative (NPV) 82.8%, 98.4%, 96.0%, 92.5%. 24 documented test, first evidence 14 (58.3%), lead time 59 days (range: 10-536). accurately resolved 94.3% indeterminate findings. provides sensitive specific approach recurrent resolving
Язык: Английский
Процитировано
0